Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01242267 · OUTCOME

Maximum Tolerated Dose of Thalidomide

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT · Source last updated 2026-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg
Interval / dispersion
Not reported
Time frame
Dose escalation will be based on the assessment of tolerability determined after the last patient of each cohort reaches day +21.

What was measured

Maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients who failed a prior treatment with dose-intense melphalan

Groups in this outcome

Phase 1

Phase 1 Dose Level 600, 800, 1000 mg of Thalidomide

Phase 2

Phase 2 Dose Level 1000 mg of Thalidomide

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 19
Phase 220

Reported measurements

Source class 1
Values in mg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase 11000Not reportedNot reportedNot reportedNot reported
Phase 21000Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1000
      2. group Id
        OG001
        value
        1000
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      20
    units
    Participants
description
Maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients who failed a prior treatment with dose-intense melphalan
groups
  1. description
    Phase 1 Dose Level 600, 800, 1000 mg of Thalidomide
    id
    OG000
    title
    Phase 1
  2. description
    Phase 2 Dose Level 1000 mg of Thalidomide
    id
    OG001
    title
    Phase 2
param Type
NUMBER
reporting Status
POSTED
time Frame
Dose escalation will be based on the assessment of tolerability determined after the last patient of each cohort reaches day +21.
title
Maximum Tolerated Dose of Thalidomide
type
PRIMARY
unit Of Measure
mg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice